How a change in FDA guidance might revolutionise MASH drug development
Transformative new shifts have taken place in the last month in the metabolic dysfunction-associated steatohepatitis (MASH) therapy space,…
Pricing group says weight-loss drugs becoming more cost-effective
By Deena Beasley (Reuters) -An influential drug pricing watchdog on Tuesday said popular GLP-1 weight-loss injections have become…
Here’s Why GreensKeeper Asset Management Added Novo Nordisk (NVO) to Its Portfolio
GreensKeeper Asset Management, an investment management company, released its second-quarter 2025 investor letter. A copy of the letter…
Ozempic reportedly faces $2 billion in lawsuits over severe side effects
Key Takeaways Trending Nearly 2,000 lawsuits allege Ozempic caused health issues including stomach paralysis and vision loss. Celebrity…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 19 August 2025 — This company announcement discloses the data of the transaction(s) made…
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
Ozempic® is the GLP-1 with the most FDA-approved uses for patients with type 2 diabetes including, improvement of…
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH,…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 12 August 2025 — This company announcement discloses the data of the transaction(s) made…
Trading in Novo Nordisk shares by board members, executives and associated persons
Novo Nordisk A/S Bagsværd, Denmark, 8 August 2025 — This company announcement discloses the data of the transaction(s) made…
Will you take Wegovy to lose weight?
Wegovy is now available in Singapore more than two years after it was approved by the Health Sciences…
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Pfizer and Novo Nordisk have underperformed the market over the past year. But both should remain major players…
Daniel Drucker, Ozempic’s father: ‘I’m very conservative. I don’t sell the drugs. I study the drugs’ | Health
Daniel Drucker, 68, speaks a little Spanish at the BBVA Foundation headquarters in Bilbao, Spain, where he’s about…